ArticleNeoplasia (New York, N.Y.)1999
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.
Article in Neoplasia (New York, N.Y.), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 145 citations in OpenAlex.
- A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.British journal of cancer · 2005Trial
- VEGFR Blockade ReducesCells · 2026Article
- Honokiol improves depression-like behaviors in rats by HIF-1α- VEGF signaling pathway activation.Frontiers in pharmacology · 2022Article
- Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines.Cancers · 2021Article
- Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches.Cancers · 2020Review
- Identification of Potent VEGF Inhibitors for the Clinical Treatment of Glioblastoma, A Virtual Screening Approach.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Gelatinolytic activity of autocrine matrix metalloproteinase-9 leads to endothelial de-arrangement in Moyamoya disease.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2018Article
- Targeting the extradomain A of fibronectin allows identification of vascular resistance to antiangiogenic therapy in experimental glioma.Oncotarget · 2018Article
- Intravital microscopy in the study of the tumor microenvironment: from bench to human application.Oncotarget · 2018Review
- Lack of VEGFR2 signaling causes maldevelopment of the intestinal microvasculature and facilitates necrotizing enterocolitis in neonatal mice.American journal of physiology. Gastrointestinal and liver physiology · 2016Article
- Heparin in malignant glioma: review of preclinical studies and clinical results.Journal of neuro-oncology · 2015Review
- Role of plasma membrane caveolae/lipid rafts in VEGF-induced redox signaling in human leukemia cells.BioMed research international · 2014Article
- VEGF activates NR2B phosphorylation through Dab1 pathway.Neuroscience letters · 2013Article
- An update in the use of antibodies to treat glioblastoma multiforme.Autoimmune diseases · 2013Review
- Article
- Article
- Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice.Nature protocols · 2010Article
- A critical analysis of current in vitro and in vivo angiogenesis assays.International journal of experimental pathology · 2009Review
- Antiangiogenic therapy in brain tumors.Expert review of neurotherapeutics · 2008Review
- The history of the angiogenic switch concept.Leukemia · 2007Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular endothelial growth factor (VEGF) plays a fundamental role in mediating tumor angiogenesis and tumor growth. Here we investigate the direct effect of a novel small molecule inhibitor of the Flk-1-mediated signal transduction pathway of VEGF, SU5416, on tumor angiogenesis and microhemodynamics of an experimental glioblastoma by using intravital multifluorescence videomicroscopy. SU5416 treatment significantly suppressed tumor growth. In parallel, SU5416 demonstrated a potent antiangiogenic activity, resulting in a significant reduction of both the total and functional vascular density of the tumor microvasculature, which indicates an impaired vascularization as well as significant perfusion failure in treated tumors. This malperfusion was not compensated for by changes in vessel diameter or recruitment of nonperfused vessels. Analyses of the tumor microcirculation revealed significant microhemodynamic changes after angiogenesis blockage such as a higher red blood cell velocity and blood flow in remnant tumor vessels when compared with controls. Our results demonstrate that the novel antiangiogenic concept of targeting the tyrosine kinase of Flk-1/KDR by means of a small molecule inhibitor represents an efficient strategy to control growth and progression of angiogenesis-dependent tumors. This study provides insight into microvascular consequences of Flk-1/KDR targeting in vivo and may have important implications for the future treatment of angiogenesis-dependent neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.